Press releases

Launch of the Phase II trial testing DNV3837 for first-line treatment of moderate to severe Clostridioides difficile infections...

DEINOVE strengthens its expertise in the genetic engineering of rare and varied microorganisms to accelerate the discovery and optimization...

New in vitro and clinical efficacy data have been published; Sphingomonas hydrophobicum extract, the active substance of Hebelys®,...

DEINOVE (Euronext Growth Paris: ALDEI), a French biotech company that uses a disruptive approach to develop innovative antibiotics and bio-...

Major Steven Zumbrun (USAMRIID [1] , U.S. Department of Defense) presented data on the in vitro assessment of DNV3681 against pathogens...

The tests aimed at validating the dosage required have confirmed a very good efficacy of the ingredient The teams are working to develop a...

Dow has selected an extract belonging to the DEINOVE proprietary strains’ bank to launch a new cosmetic active ingredient for skin care...

Her proven experience in the beauty industry, particularly within the L'Oréal Group, will be a key asset in DEINOVE's innovation approach...

The USAMRIID (United States Army Medical Research Institute of Infectious Diseases) evaluated DNV3681 against Bacillus anthracis that...

Having reached a sufficient number of clinical centers, Phase II clinical trial testing the antibiotic candidate DNV3837 in Clostridioides[...